메뉴 건너뛰기




Volumn 119, Issue 15, 2013, Pages 2754-2764

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Author keywords

EGFR mutation; erlotinib; KRAS mutation; non small cell lung cancer; pemetrexed; pretreated patients

Indexed keywords

CYANOCOBALAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; PEMETREXED;

EID: 84880570204     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28132     Document Type: Article
Times cited : (109)

References (32)
  • 1
    • 0028843552 scopus 로고
    • Chemotherapy in non-small cell lung cancer - A meta-analysis using updated data on individual patients from 52 randomized clinical trials. non-small cell Lung Cancer Collaborative Group
    • Chemotherapy in non-small cell lung cancer-a meta-analysis using updated data on individual patients from 52 randomized clinical trials. non-small cell Lung Cancer Collaborative Group. BMJ. 1995; 311: 899-909.
    • (1995) BMJ , vol.311 , pp. 899-909
  • 2
    • 0027367248 scopus 로고
    • Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough?
    • Grilli R, Oxyman A, Julian J,. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol. 1993; 11: 1866-1872.
    • (1993) J Clin Oncol , vol.11 , pp. 1866-1872
    • Grilli, R.1    Oxyman, A.2    Julian, J.3
  • 3
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095-2103.
    • (2000) J Clin Oncol , vol.18 , pp. 2095-2103
    • Shepherd, F.1    Dancey, J.2    Ramlau, R.3
  • 4
    • 0034095853 scopus 로고    scopus 로고
    • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens
    • Fossella F, DeVore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000; 18: 2354-2362.
    • (2000) J Clin Oncol , vol.18 , pp. 2354-2362
    • Fossella, F.1    Devore, R.2    Kerr, R.3
  • 5
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd F, Fossella F, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597.
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.2    Fossella, F.3
  • 6
    • 3042575322 scopus 로고    scopus 로고
    • Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent
    • Adjei A,. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004; 10: S4276-S4280.
    • (2004) Clin Cancer Res , vol.10
    • Adjei, A.1
  • 7
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 8
    • 0347364778 scopus 로고    scopus 로고
    • Targeting the epidermal growth factor receptor in non-small cell lung cancer
    • Herbst R, Bunn P, Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003; 9: 5813-5824.
    • (2003) Clin Cancer Res , vol.9 , pp. 5813-5824
    • Herbst, R.1    Bunn Jr., P.2
  • 10
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 11
    • 22044453790 scopus 로고    scopus 로고
    • Erlotinib in lung cancer-molecular and clinical predictors of outcome
    • Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-145.
    • (2005) N Engl J Med , vol.353 , pp. 133-145
    • Tsao, M.S.1    Sakurada, A.2    Cutz, J.C.3
  • 12
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 13
    • 77953930730 scopus 로고    scopus 로고
    • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    • Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 363: 2380-2388.
    • (2010) N Engl J Med , vol.363 , pp. 2380-2388
    • Maemondo, M.1    Inoue, A.2    Kobayashi, K.3
  • 14
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomized phase 3 trial
    • Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
    • (2010) Lancet Oncol , vol.11 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3
  • 15
    • 79960889662 scopus 로고    scopus 로고
    • Erlotinib vs chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicenter, open-label, randomized, phase 3 study
    • Zhou C, Wu YL, Chen G, et al. Erlotinib vs chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
    • (2011) Lancet Oncol , vol.12 , pp. 735-742
    • Zhou, C.1    Wu, Y.L.2    Chen, G.3
  • 16
    • 80755181119 scopus 로고    scopus 로고
    • Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer
    • Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29: 4068-4070.
    • (2011) J Clin Oncol , vol.29 , pp. 4068-4070
    • Brugger, W.1    Triller, N.2    Blasinska-Morawiec, M.3
  • 17
    • 52049090365 scopus 로고    scopus 로고
    • Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21
    • Zhu CQ, Santos GC, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol. 2008; 26: 4268-4275.
    • (2008) J Clin Oncol , vol.26 , pp. 4268-4275
    • Zhu, C.Q.1    Santos, G.C.2    Ding, K.3
  • 18
    • 61449341457 scopus 로고    scopus 로고
    • Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer. An analysis of patients from German centers in the TRUST study
    • Schneider CP, Heigener D, Schott von Romer K, et al. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer. An analysis of patients from German centers in the TRUST study. J Thorac Oncol. 2008; 3: 1446-1453.
    • (2008) J Thorac Oncol , vol.3 , pp. 1446-1453
    • Schneider, C.P.1    Heigener, D.2    Schott Von Romer, K.3
  • 19
    • 52749099497 scopus 로고    scopus 로고
    • Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer
    • Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9: 962-972.
    • (2008) Lancet Oncol , vol.9 , pp. 962-972
    • Linardou, H.1    Dahabreh, I.J.2    Kanaloupiti, D.3
  • 20
    • 77955096407 scopus 로고    scopus 로고
    • KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analyses of 22 studies
    • Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analyses of 22 studies. Lung Cancer. 2010; 69: 272-278.
    • (2010) Lung Cancer , vol.69 , pp. 272-278
    • Mao, C.1    Qiu, L.X.2    Liao, R.Y.3
  • 21
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 22
    • 12344312699 scopus 로고    scopus 로고
    • National Cancer Institute. Bethesda, MD: National Cancer Institute;. Available at [Access April 18, 2013]
    • National Cancer Institute. Common Toxicity Criteria for Adverse Events. Bethesda, MD: National Cancer Institute; 2012. Available at: http://www.eortc.be/services/doc/ctc/ctcv20-4-30-992.pdf. [Access April 18, 2013].
    • (2012) Common Toxicity Criteria for Adverse Events
  • 23
    • 51449101924 scopus 로고    scopus 로고
    • Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    • Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 2008; 99: 923-929.
    • (2008) Br J Cancer , vol.99 , pp. 923-929
    • Kalikaki, A.1    Koutsopoulos, A.2    Trypaki, M.3
  • 24
    • 84857501696 scopus 로고    scopus 로고
    • Erlotinib vs docetaxel or pemetrexed as second-line therapy in patients with advanced NSCLC and poor prognosis: Efficacy and safety results from the phase III TITAN study
    • Ciuleanu T, Stelmakh L, Cicenas S, et al. Erlotinib vs docetaxel or pemetrexed as second-line therapy in patients with advanced NSCLC and poor prognosis: efficacy and safety results from the phase III TITAN study. Lancet Oncol. 2012; 3: 300-308.
    • (2012) Lancet Oncol , vol.3 , pp. 300-308
    • Ciuleanu, T.1    Stelmakh, L.2    Cicenas, S.3
  • 25
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib vs docetaxel in previously treated non-small cell lung cancer (INTEREST): A randomized phase III trial
    • Kim ES, Hirsh V, Mok T, et al. Gefitinib vs docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet. 2008; 372: 1809-1818.
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 26
    • 52049125250 scopus 로고    scopus 로고
    • Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer
    • Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008; 26: 4244-4252.
    • (2008) J Clin Oncol , vol.26 , pp. 4244-4252
    • Maruyama, R.1    Nishiwaki, Y.2    Tamura, T.3
  • 27
    • 76749154617 scopus 로고    scopus 로고
    • Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
    • Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010; 16: 1307-1314.
    • (2010) Clin Cancer Res , vol.16 , pp. 1307-1314
    • Lee, D.H.1    Park, K.2    Kim, J.H.3
  • 28
    • 77649222572 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial
    • Douillard J-Y, Shepherd F, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2009; 28: 744-752.
    • (2009) J Clin Oncol , vol.28 , pp. 744-752
    • Douillard, J.-Y.1    Shepherd, F.2    Hirsh, V.3
  • 29
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-967.
    • (2009) N Engl J Med , vol.361 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3
  • 30
    • 84866927445 scopus 로고    scopus 로고
    • TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR [abstract]
    • Abstract LBA7501
    • Garassino MC, Martelli O, Bettini A, et al. TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR [abstract]. J Clin Oncol. 2012; 30 (18 suppl). Abstract LBA7501.
    • (2012) J Clin Oncol. , vol.30 , Issue.18 SUPPL.
    • Garassino, M.C.1    Martelli, O.2    Bettini, A.3
  • 31
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): A multicenter, open-label, randomized phase 3 trial
    • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 3: 239-246.
    • (2012) Lancet Oncol , vol.3 , pp. 239-246
    • Rosell, R.1    Carcereny, E.2    Gervais, R.3
  • 32
    • 79953029071 scopus 로고    scopus 로고
    • Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed
    • Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 2011; 4: 774-780.
    • (2011) J Thorac Oncol , vol.4 , pp. 774-780
    • Camidge, D.R.1    Kono, S.A.2    Lu, X.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.